Bumper Offer - Urjas oil Just @ Rs. 1
Arvast 30 Tablet is a prescription medicine that is available as a Tablet. High Cholesterol are some of its major therapeutic uses. Secondary and off-label uses of Arvast 30 Tablet have also been mentioned below.
The optimal dosage of Arvast 30 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Refer to the dosage section for a detailed discussion.
While these are the most often observed Arvast 30 Tablet side effects, there are can be others also. These have been listed below. Usually, these side effects of Arvast 30 Tablet go away soon, and do not persist beyond the duration of the treatment. However, if these continue for a longer time, consult your doctor right away.
In addition, Arvast 30 Tablet's effect is Severe during pregnancy and Mild for lactating mothers. Further, the section on Arvast 30 Tablet related warnings talks about Arvast 30 Tablet's effects on the liver, heart and kidney.
Arvast 30 Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. Kidney Disease, Hypothyroidism, Drug Allergy are examples of such conditions. Other contraindications of Arvast 30 Tablet have been discussed in the sections ahead.
Besides this, Arvast 30 Tablet may also have severe interaction with some medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Arvast 30 Tablet is considered safe while driving, and is addictive.
Arvast 30 Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
Based on research, the following side effects have been observed when Arvast 30 Tablet is used -
Severe
Moderate
Mild
Is the use of Arvast 30 Tablet safe for pregnant women?
Arvast shows severe side effect on pregnant women. For this reason, pregnant women should only take it after taking medical advice.
Is the use of Arvast 30 Tablet safe during breastfeeding?
Arvast may have very limited harmful effects for breastfeeding women.
What is the effect of Arvast 30 Tablet on the Kidneys?
Kidney can be affected by Arvast. If you experience any unwanted effects of this drug, stop taking it. You should take it again only after medical advice.
What is the effect of Arvast 30 Tablet on the Liver?
The liver can be affected by Arvast. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart Arvast only after medical advice.
What is the effect of Arvast 30 Tablet on the Heart?
Arvast is rarely harmful for the heart.
Arvast 30 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Arvast 30 Tablet unless your doctor advises you to do so -
Is this Arvast 30 Tablet habit forming or addictive?
Forming a habit of Arvast 30 Tablet has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
Yes, you can comfortably use machinery or drive after taking Arvast 30 Tablet since it will not make you feel sleepy.
Is it safe?
Yes, but take Arvast 30 Tablet only as per medical advice.
Is it able to treat mental disorders?
No, the use of Arvast 30 Tablet in mental disorders is not effective.
Interaction between Food and Arvast 30 Tablet
When consumed with certain foods, Arvast 30 Tablet may take longer to have an effect. Contact your doctor about this.
Interaction between Alcohol and Arvast 30 Tablet
Consumption of alcohol and Arvast 30 Tablet together may have severe effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Crestor (rosuvastatin calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 636,637
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Crestor (rosuvastatin calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 636,637
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Durlaza (aspirin)
KD Tripathi. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 195-199
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 191-194
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Plavix (clopidogrel bisulfate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 630-631
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 335-336
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Crestor (rosuvastatin calcium)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 636,637
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 646-650
